The effect of omission of adjuvant radiotherapy after neoadjuvant chemotherapy and breast conserving surgery with a pathologic complete response

被引:5
作者
Mandish, Steven F. [1 ]
Gaskins, Jeremy T. [2 ]
Yusuf, Mehran B. [1 ]
Amer, Yomna M. [3 ]
Eldredge-Hindy, Harriet [1 ]
机构
[1] Univ Louisville Hosp, Dept Radiat Oncol, Louisville, KY USA
[2] Univ Louisville, Dept Bioinformat & Biostat, Louisville, KY 40202 USA
[3] Univ Louisville, Sch Med, Louisville, KY 40202 USA
关键词
RADIATION-THERAPY; CANCER; STAGE; IRRADIATION; DISTANCE; OUTCOMES; IMPACT; TRASTUZUMAB; POPULATION; CARCINOMA;
D O I
10.1080/0284186X.2020.1797161
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective(s) Neoadjuvant chemotherapy (NAC) is a standard of care for locally advanced breast cancers. Adjuvant radiotherapy (RT) after NAC is an area of active research. We hypothesize overall survival (OS) is not altered by omitting RT in women with a pathologic complete response (pCR) to NAC after breast conserving survery (BCS). Methods Patients from the National Cancer Database who underwent NAC, BCS, and had a pCR were included. Inflammatory disease, <6 months follow up, and unknown variables were excluded. Descriptive statistics characterized the retained cohort. Logistic regression analyzed the influence of variables on the rate of RT omission. Cox proportional hazard modeling analyzed the influence of prognostic variables on OS. Results Of 5383 women included, 364 (7%) omitted RT. 5-year OS was 94.1% with RT, 93% without. RT omission was most likely in women >70yo (adjusted OR2.4, 95%CI 1.58-3.65,p < .0001;reference 40-49 yo), Hispanic (AOR 1.73, 95%CI 1.19-2.52,p = .0044; reference non-Hispanic), >= 20 miles from treatment facility (20-49 miles; AOR 1.45, 95%CI 1.09-1.93,p = .0109: >50 miles; AOR 2.02, 95%CI 1.42-2.87,p < .0001;reference 0-19 miles), grade 1 (AOR 4.29, 95%CI 2.16-8.51,p < .0001; reference grade 3), and clinical T4 disease (AOR 3.17, 95%CI 1.74-5.79,p = .0002; reference T0/1). Women >= 60yo (60-69: AHR 2.33, 95%CI 1.41-3.83,p = .0009:70+:AHR 2.4, 95%CI 1.24-4.62,p = .0092; reference 40-49) and with N1 and N3 disease (N1: AHR 1.67, 95% CI 2.28-3.24,p = .0034; N3: AHR3.37,95%CI2.01-5.65,p < .0001) showed increased death. Triple-positive (AHR 0.18, 95%CI 0.07-0.43,p = .0002) and HER2+ patients (AHR 0.44, 95%CI 0.30-0.64,p < .0001) had improved OS compared to triple-negative disease. No survival difference was seen with omission of RT (log-rank test:p = .1783; Cox model AHR 1.33, 95%CI 0.76-2.31,p = .3181). Conclusion Women >= 70, of Hispanic origin, living >= 20 miles from treatment facility, and grade 1 disease were more likely to omit RT. HER2+ patients had favorable OS, while older age and N3 disease were negative prognostic factors. Omitting RT after a pCR to NAC and BCS was not found to affect OS.
引用
收藏
页码:1210 / 1217
页数:8
相关论文
共 31 条
  • [1] Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
    Alberro, J. A.
    Ballester, B.
    Deulofeu, P.
    Fabregas, R.
    Fraile, M.
    Gubern, J. M.
    Janer, J.
    Moral, A.
    de Pablo, J. L.
    Penalva, G.
    Puig, P.
    Ramos, M.
    Rojo, R.
    Santesteban, P.
    Serra, C.
    Sola, M.
    Solarnau, L.
    Solsona, J.
    Veloso, E.
    Vidal, S.
    Abe, O.
    Abe, R.
    Enomoto, K.
    Kikuchi, K.
    Koyama, H.
    Masuda, H.
    Nomura, Y.
    Ohashi, Y.
    Sakai, K.
    Sugimachi, K.
    Toi, M.
    Tominaga, T.
    Uchino, J.
    Yoshida, M.
    Coles, C. E.
    Haybittle, J. L.
    Moebus, V.
    Leonard, C. F.
    Calais, G.
    Garaud, P.
    Collett, V.
    Davies, C.
    Delmestri, A.
    Sayer, J.
    Harvey, V. J.
    Holdaway, I. M.
    Kay, R. G.
    Mason, B. H.
    Forbe, J. F.
    Franci, P. A.
    [J]. LANCET ONCOLOGY, 2018, 19 (01) : 27 - 39
  • [2] Barranger E, 2015, Clin Breast Cancer, V15, P231
  • [3] Using the National Cancer Database for Outcomes Research
    Boffa, Daniel J.
    Rosen, Joshua E.
    Mallin, Katherine
    Loomis, Ashley
    Gay, Greer
    Palis, Bryan
    Thoburn, Kathleen
    Gress, Donna
    McKellar, Daniel P.
    Shulman, Lawrence N.
    Facktor, Matthew A.
    Winchester, David P.
    [J]. JAMA ONCOLOGY, 2017, 3 (12) : 1722 - 1728
  • [4] Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen
    Buzdar, Aman U.
    Valero, Vicente
    Ibrahim, Nuhad K.
    Francis, Deborah
    Broglio, Kristine R.
    Theriault, Richard L.
    Pusztai, Lajos
    Green, Marjorie C.
    Singletary, Sonja E.
    Hunt, Kelly K.
    Sahin, Aysegul A.
    Esteva, Francisco
    Symmans, William F.
    Ewer, Michael S.
    Buchholz, Thomas A.
    Hortobagyi, Gabriel N.
    [J]. CLINICAL CANCER RESEARCH, 2007, 13 (01) : 228 - 233
  • [5] Travel distance and season of diagnosis affect treatment choices for women with early-stage breast cancer in a predominantly rural population (United States)
    Celaya, Maria O.
    Rees, Judy R.
    Gibson, Jennifer J.
    Riddle, Bruce L.
    Greenberg, E. Robert
    [J]. CANCER CAUSES & CONTROL, 2006, 17 (06) : 851 - 856
  • [6] Cortazar P, 2019, LANCET, V393, P986
  • [7] Invasive lobular carcinoma classic type: Response to primary chemotherapy and survival outcomes
    Cristofanilli, M
    Gonzalez-Angulo, A
    Sneige, N
    Kau, SW
    Broglio, K
    Theriault, RL
    Valero, V
    Buzdar, AU
    Kuerer, H
    Buccholz, TA
    Hortobagyi, GN
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (01) : 41 - 48
  • [8] Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review
    Dawood, Shaheenah
    Broglio, Kristine
    Buzdar, Aman U.
    Hortobagyi, Gabriel N.
    Giordano, Sharon H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) : 92 - 98
  • [9] Disparities in the Application of Adjuvant Radiotherapy After Breast-Conserving Surgery for Early Stage Breast Cancer
    Dragun, Anthony E.
    Huang, Bin
    Tucker, Thomas C.
    Spanos, William J.
    [J]. CANCER, 2011, 117 (12) : 2590 - 2598
  • [10] Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials
    Darby S.
    McGale P.
    Correa C.
    Taylor C.
    Arriagada R.
    Clarke M.
    Cutter D.
    Davies C.
    Ewertz M.
    Godwin J.
    Gray R.
    Pierce L.
    Whelan T.
    Wang Y.
    Peto R.
    Albain K.
    Anderson S.
    Barlow W.
    Bergh J.
    Bliss J.
    Buyse M.
    Cameron D.
    Carrasco E.
    Coates A.
    Collins R.
    Costantino J.
    Cuzick J.
    Davidson N.
    Davies K.
    Delmestri A.
    Di Leo A.
    Dowsett M.
    Elphinstone P.
    Evans V.
    Gelber R.
    Gettins L.
    Geyer C.
    Goldhirsch A.
    Gregory C.
    Hayes D.
    Hill C.
    Ingle J.
    Jakesz R.
    James S.
    Kaufmann M.
    Kerr A.
    MacKinnon E.
    McHugh T.
    Norton L.
    Ohashi Y.
    [J]. LANCET, 2011, 378 (9804) : 1707 - 1716